InsidersTradesSigma
Follow the 에스케이바이오팜 stock price and the full directors' dealings record of the company, a publicly traded company based in South Korea. Shares are quoted on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, 에스케이바이오팜 has logged 7 reports. Market capitalisation: €6,014.5bn. The latest transaction was reported on 31 August 2026 (Purchase). Among the most active insiders: SK. Every trade is free.
5
Insider Decl.
n/a
Thresholds
€719m
3 ops.
Buy Volume
n/a
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 에스케이바이오팜 Buy (bullish), based on 12 analysts. Average price target: ₩131,167.
18Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 5,616 of 29,114 companies
67.2
score / 100
Value41
Quality93
FCF yld2.4%
Earn yld4.4%
EV/EBITDA34.5x
ROE48%
Gross mgn94%
Net mgn38%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 31 August 2026
Declarations7 total
Other
Other
7 of 7 declarations
About 에스케이바이오팜
SK Biopharmaceuticals is a company in the health and pharmaceutical sector, listed on the XKRX exchange. It focuses on developing innovative treatments for neurological disorders.